hexadecyl hydroperoxide | 4439-43-4

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氢过氧化物
• 英文名称: hexadecyl hydroperoxide
• 英文别名: Hexadecylhydroperoxid；1-hydroperoxyhexadecane
• CAS: 4439-43-4
• 化学式: C₁₆H₃₄O₂
• 分子量: 258.445
• InChiKey: KBDHWXWYYVIQNF-UHFFFAOYSA-N

物化性质

• 熔点：
  42-44 °C
• 沸点：
  361.4±11.0 °C(Predicted)
• 密度：
  0.871±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  18
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-hexadecyl-N'-tosylhydrazine 在 sodium peroxide 、 双氧水 作用下， 生成 hexadecyl hydroperoxide
  参考文献：
  名称：

  Oxidation of n-alkyl-n'-tosylhydrazines to hydroperoxides

  摘要：

  DOI：

  10.1016/0040-4020(78)88048-x

文献信息

• NOVEL DERIVATIVES OF SINAPINIC ACID AND THE COSMETIC OR PHARMACEUTICAL USES THEREOF
  申请人：BASF Beauty Care Solutions France SAS

  公开号：US20150342847A1

  公开（公告）日：2015-12-03

  The present invention relates to a compound of general formula (I) below: in which: R 1 , R 2 and R 3 independently of one another represent a hydrogen atom; a C1-12 alkyl group; a C2-12 alkenyl group; a C2-12 alkynyl group; a C3-12 cycloalkyl group; a C1-12 acyl group; a sulfonyl group or a phosphonate group; represents a CH 2 —CH 2 group or a CH═CH group; n is an integer between 1 and 3; or a salt thereof. The invention further relates to a process for synthesizing this compound or salt, to a composition comprising it, to its cosmetic use, more particularly as a depigmenting agent and/or as a radical scavenger, to a cosmetic care process, and to its use as a drug, advantageously intended for preventing and/or treating pathological hyperpigmentation and/or inflammation.

  本发明涉及以下一般式（I）的化合物： 其中： R1、R2和R3分别独立地表示氢原子；C1-12烷基基团；C2-12烯基基团；C2-12炔基基团；C3-12环烷基基团；C1-12酰基团；磺酰基或膦酸酯基团；表示CH2— 基团或CH═CH基团；n是1到3之间的整数；或其盐。该发明还涉及合成该化合物或盐的过程，包括它的组合物，其化妆品用途，尤其作为脱色剂和/或自由基清除剂，化妆保养过程，以及其作为药物的用途，有利于预防和/或治疗病理性色素沉着和/或炎症。
• [EN] NOVEL METHOD OF USE AND COMPOSITIONS<br/>[FR] NOUVEAU PROCÉDÉ D'UTILISATION ET COMPOSITIONS
  申请人：GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC

  公开号：WO2017074902A1

  公开（公告）日：2017-05-04

  The present invention is directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1- to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. The present invention is also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3 % w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

  本发明涉及一种用于改善患者使用中的局部药物或化妆品配方的闭合性的方法，包括向配方中添加至少0.1%至约10%重量/重量的一种或多种甘油的单脂肪酸酯和/或一种或多种乙二醇的单脂肪酸酯，或其混合物。本发明还涉及一种用于维持患者角质层皮肤屏障效率的方法，包括向该患者的皮肤上涂抹含有至少3%重量/重量的一种或多种甘油的单脂肪酸酯和/或一种或多种乙二醇的单脂肪酸酯，或其混合物的药物或化妆品配方。
• Hydrophilic-Hydrophobic derivatives of polygalactomannans containing tertiary amine functionality
  申请人：STEIN, HALL & CO., INC.

  公开号：EP0496584A2

  公开（公告）日：1992-07-29

  Triple derivatives of polygalactomannan, i.e. a dialkylaminoalkyl ether-hydroxyalkyl ether - long aliphatic chain ether of polygalactomannan, are useful as thickening agents for aqueous fluids.

  聚半乳糖甘露聚糖的三重衍生物，即聚半乳糖甘露聚糖的二烷基氨基烷基醚-羟基烷基醚-长脂肪链醚，可用作水性流体的增稠剂。
• METHOD OF DETERMINING GENETIC POLYMORPHISM FOR JUDGMENT OF DEGREE OF DISEASE RISK, METHOD OF JUDGING DEGREE OF DISEASE RISK, AND JUDGMENT ARRAY
  申请人：Signpost Corporation

  公开号：EP1684202A1

  公开（公告）日：2006-07-26

  The present invention provides a method of assessing disease risk, which enables accurate assessment of disease risk (i.e., the likelihood of onset of a disease, the probability of progression of the disease, etc.) and is available for the prevention and treatment of disease; and a method of determining genetic polymorphisms for assessing disease risk, usable for such disease risk assessment and like purposes. It also provides an array, a kit for analyzing a genetic polymorphism, an apparatus for assessing disease risk, etc., for use in disease risk assessment. The main characteristic of the risk assessment is the use of polymorphisms or polymorphism set(s) negatively associated with (resistant to) a target disease, and especially the combined use of polymorphisms or polymorphism set(s) negatively associated with the disease and polymorphism(s) or polymorphism set(s) positively associated with the diseases.

  本发明提供了一种评估疾病风险的方法，可准确评估疾病风险（即疾病发病的可能性、疾病进展的概率等），可用于疾病的预防和治疗；还提供了一种用于评估疾病风险的基因多态性测定方法，可用于此类疾病风险评估和类似目的。它还提供了用于疾病风险评估的阵列、分析基因多态性的试剂盒、评估疾病风险的仪器等。风险评估的主要特点是使用与目标疾病负相关（抗性）的多态性或多态性组，特别是结合使用与疾病负相关的多态性或多态性组和与疾病正相关的多态性或多态性组。
• GLUTAMATE DECARBOXYLASE MUTANT
  申请人：Tokyo University of Science, Educational Foundation

  公开号：EP1865063A1

  公开（公告）日：2007-12-12

  Thermally stable GAD65 mutants are provided, which are useful for early diagnosis of insulin-dependent diabetes mellitus and retain antigenicity to pancreatic islet-β-cell-specific autoantibodies. Specifically, error-prone PCR is performed using a GAD65 gene as a template. A host microorganism is transformed with the thus obtained random gene library. Screening is performed using as an indicator the presence or the absence of antigenicity of the expressed protein to a pancreatic islet-β-cell-specific autoantibody after heat treatment. Thus, a GAD65 mutant having thermostability and antigenicity can be obtained.

  本研究提供了热稳定的 GAD65 突变体，这些突变体可用于胰岛素依赖型糖尿病的早期诊断，并能保持对胰岛-β 细胞特异性自身抗体的抗原性。具体来说，以 GAD65 基因为模板进行易错 PCR。用由此获得的随机基因库转化宿主微生物。在热处理后，以表达的蛋白对胰岛-β细胞特异性自身抗体是否具有抗原性为指标进行筛选。因此，可以获得具有热稳定性和抗原性的 GAD65 突变体。